Why technology standards are critical for Quantum-Safe Security

Safeguard Insights

December 16, 2011

Week in Review: VC 2012 Predictions and MediaMath Crowned King of DSPs

In the latest VentureView report, the National Venture Capital Association and Dow Jones & Co. reported that 63 percent of VCs think their portfolio companies…

Posted by John E. Shave III

November 18, 2011

Week in Review: Convergence between Life Sciences and Technology and A Look at New Partner Company Medivo

The convergence between life sciences and technology cannot be ignored. That’s why at Safeguard Scientifics, we consolidated of our life sciences and technology deal teams.…

Posted by John E. Shave III

September 9, 2011

Week in Review: Job Creation, Microsoft Partnerships, and Electronic Eyeglasses

This week, we announced details for our Investor Day 2011, scheduled for Tuesday, October, 4 at The Yale Club of New York City. It’s a great…

Posted by John E. Shave III

June 17, 2011

Week in Review: IPOs, Entrepreneurship and 40 Years Trading on the NYSE

More IPO buzz this week. On Wednesday, its first day of trading, Pandora shares were as high as $26. The excitement dwindled a bit on…

Posted by John E. Shave III

May 5, 2011

Safeguard Scientifics Honored with Investment Deal of the Year at PACT Enterprise Awards

Last night, I had the pleasure of attending the Greater Philadelphia Alliance for Capital and Technologies (PACT) 18th Annual Enterprise Awards. For nearly 60 years,…

Posted by Peter J. Boni

August 26, 2010

Safeguard CEO featured on TheStreet.com

Last week, Safeguard Scientifics’ President and CEO Peter J. Boni sat down with Gregg Greenberg of TheStreet.com to discuss the emergence of IPO candidates from…

Posted by John E. Shave III

August 16, 2010

IPOs: A Financing Event

On the heels of continued IPO activity, there has been a flurry of media coverage — both positive and negative — regarding the companies that…

Posted by Peter J. Boni

July 1, 2010

The Next Frontier: Opportunities in Regenerative Medicine

While there are a wealth of opportunities to deploy capital in a variety of life sciences companies, the evolution and potential long-term impact of regenerative…

Posted by James A. Datin

Content